Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis

Journal of Rheumatology

Volumn 37, Issue 7, 2010, Pages 1508-1512

  Chandran, Vinod ^a   Siannis, Fotios ^b,c   Rahman, Proton ^d   Pellett, Fawnda J ^e   Farewell, Vernon T ^c   Gladman, Dafna D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Drug response; Drug survival; Drug toxicity; Pharmacogenetics; Psoriatic arthritis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AZATHIOPRINE; DIHYDROFOLATE REDUCTASE; FOLIC ACID; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISONE; REDUCED FOLATE CARRIER; SALAZOSULFAPYRIDINE;

ADULT; ALLELE; ARTICLE; COHORT ANALYSIS; DATA BASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; FISHER EXACT TEST; GENOTYPE; HUMAN; JOINT RADIOGRAPHY; LIVER FUNCTION; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSORIATIC ARTHRITIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COHORT STUDIES; FEMALE; FOLIC ACID; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 77954449063     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091311     Document Type: Article

References (37)

1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14-7.
2. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
3. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64. (Pubitemid 351509657)
4. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008;35:469-71. (Pubitemid 351374423)
5. Cronstein BN. Pharmacogenetics in the rheumatic diseases. Bull NYU Hosp Jt Dis 2006;64:16-9.
6. Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006;54:1366-77.
7. Kremer JM. Methotrexate pharmacogenomics. Ann Rheum Dis 2006;65:1121-3.
8. Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JN, Smith CH. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 2007;127:1860-7.
9. Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008;128:1925-9.
10. Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009;160:438-41.
11. Rahman P, O'Rielly DD. Psoriatic arthritis: genetic susceptibility and pharmacogenetics. Pharmacogenomics 2008;9:195-205.
12. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Invest 2006;26:55-62.
13. Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005;4:723-30.
14. Belzunegui J, Intxausti JJ, De Dios JR, Lopez-Dominguez L, Queiro R, Gonzalez C, et al. Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate. Clin Exp Rheumatol 2001;19:727-30.
15. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg J, Kavanaugh A, et al. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010;69:43-7.
16. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
17. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med 1987;62:127-41. (Pubitemid 17042878)
18. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44. (Pubitemid 8387357)
19. Gladman DD, Farewell V, Buskila D, Goodman R, Hamilton L, Langevitz P, et al. Reliability of measurements of active and damaged joints in psoriatic arthritis. J Rheumatol 1990;17:62-4. (Pubitemid 20070571)
20. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G, Salonen D. Radiological assessment in psoriatic arthritis. Br J Rheumatol 1998;37:760-5.
21. Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006;7:781-91.
22. Jorgensen AL, Williamson PR. Methodological quality of pharmacogenetic studies: issues of concern. Stat Med 2008;27:6547-69.
23. Hughes LB, Beasley TM, Patel H, Tiwari HK, Morgan SL, Baggott JE, et al. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006;65:1213-8.
24. Huennekens FM. In search of dihydrofolate reductase. Protein Sci 1996;5:1201-8.
25. Goto Y, Yue L, Yokoi A, Nishimura R, Uehara T, Koizumi S, et al. A novel single-nucleotide polymorphism in the 3′-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res 2001;7:1952-6.
26. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA 2007;104:13513-8.
27. van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-30.
28. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12:183-90.
29. Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T, et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 2004;63:1227-31.
30. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003;11:593-600.
31. Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009;36:539-45.
32. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995;9:619-32.
33. Nakamachi Y, Koshiba M, Nakazawa T, Hatachi S, Saura R, Kurosaka M, et al. Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts. Arthritis Rheum 2003;48:668-74. (Pubitemid 36302002)
34. Riksen NP, Barrera P, van den Broek PH, van Riel PL, Smits P, Rongen GA. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis 2006;65:465-70.
35. Wessels JA, Kooloos WM, Jonge RD, De Vries-Bouwstra JK, Allaart CF, Linssen A, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2006;54:2830-9.
36. Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007;56:1765-75.
37. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii49-54.